What is the current stock price of Oncorus, Inc. (ONCR)?

As of the latest market data, Oncorus, Inc. (ONCR) is trading at $0.13. The stock has seen a loss of -3.08% today.

Does Oncorus, Inc. (ONCR) pay a dividend?

Based on current data, Oncorus, Inc. does not have a confirmed active dividend policy.

What is the market cap of Oncorus, Inc.?

The current market capitalization of Oncorus, Inc. (ONCR) is approximately unavailable.

ONCR

Oncorus, Inc.·Healthcare

0.13

3.077%(−0.00)

Market Closed

Last Updated: — ET

52W L: $0.0152W H: $0.47

Company Profile

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2020-10-02

Beta

1.95

Websitewww.oncorus.com↗